tbuckley/cabot-search huggingface dataset:
1076O Adjuvant nivolumab (NIVO) vs ipilimumab (IPI) in resected stage III/IV melanoma: 4-y recurrence-free and overall survival (OS) results from CheckMate 238
Authors: J. Weber, M. Del Vecchio, M. Mandala, H. Gogas, A.M. Arance Fernandez, S. Dalle, C.L. Cowey, M. Schenker, J-J. Grob, V. Chiarion Sileni, I. Márquez-Rodas, M.O. Butler, M. Maio, M. Middleton, L. de la Cruz Merino, M. Lobo, V. de Pril, J. Larkin, P.A. Ascierto
Journal: Annals of Oncology (2020)
1531P FOLFIRINOX relative dose intensity (RDI) and disease control in advanced pancreatic cancer patients (APC)
Authors: A. Vary, L. Lebellec, M-C. Le Deley, N. Penel, C. Cheymol, E. Rad, F. El Hajbi, J. Edeline, F. Di Fiore, A-M. Bimbai, A. Turpin
Journal: Annals of Oncology (2020)
1156O Surufatinib (S) for patients (Pts) with advanced pancreatic neuroendocrine tumours (SANET-p): A randomized, double-blind, placebo (P)-controlled phase III trial (NCT02589821)
Authors: J. Xu, L. Shen, C. Bai, J. Li, Z. Zhou, X. Yu, Z. Li, E. Li, X. Yuan, Y. Chi, Y. Yin, W. Lou, N. Xu, Y. Bai, T. Zhang, D. Xiu, X. Wang, J. Li, S. Fan, W. Su
Journal: Annals of Oncology (2020)
1357P Outcomes of treated patients with EGFR-mutated advanced or metastatic non-small cell lung cancer harboring exon 19 deletions or L858R substitution (Exon 21) mutations: A systematic literature review
Authors: K.B. Winfree, X. Wang, U. Kiiskinen, G. Reppen, C. Papagiannopoulos, M. Nassim, K. Haeussler, D. So, K. Taipale, C. Molife, M-H. Jen, S. Traore, R. Varea
Journal: Annals of Oncology (2020)
1613P_PR An estimate of the 2-year oncology workload generated by each new patient: A real-world study
Authors: S.K. Garattini, A.M. Minisini, F. Valent, C. Riosa, D. Zara, M. Giavarra, C. Corvaja, L. Palmero, C. Noto, G. Fasola
Journal: Annals of Oncology (2020)
LBA66_PR Disparities in access to oncology clinical trials in Europe in the period 2009-2019
Authors: A. Carneiro, T.M.S. Amaral, M. Brandao, M. Scheffler, K. Bol, R. Ferrara, M. Jalving, G. Lo Russo, I. Marquez-Rodas, A. Matikas, L. Mezquita, G. Morgan, C.E. Onesti, S. Pilotto, E. Saloustros, D. Trapani
Journal: Annals of Oncology (2020)
579P MORAb-109: A site-specific eribulin-conjugated ADC targeting human mesothelin
Authors: E. Albone, X. Cheng, A. Verdi, S. Jacob, S. Fernando, K. Furuuchi, J. Fulmer, A. Soto, B. Drozdowski, Y. Mano, Y. Nakatani, T. Uenaka
Journal: Annals of Oncology (2020)
1711P SARS-CoV-2 infection in prostate cancer patients: Data from a high-incidence area in Italy
Authors: A. Sbrana, F. Paolieri, F. Bloise, A. Nuzzo, S. Manacorda, E. Sammarco, F. Manfredi, C. Mercinelli, G. Gadducci, N. Giannini, A. Antonuzzo, F. Paiar, A. Falcone, F. Pasqualetti, L. Galli
Journal: Annals of Oncology (2020)
280MO Progression free survival with endocrine therapy, before or after chemotherapy, in patients with hormone receptor-positive/HER2-negative metastatic breast cancer in a large multicenter national observational study
Authors: P. Corbaux, A. Lardy-Cleaud, M. Alexandre, M. Fontanilles, C. Levy, A.A. Viansone, A. Mailliez, M. Debled, A. Gonçalves, F. Le Du, F. Lerebours, J-M. Ferrero, J-C. Eymard, M-A. Mouret-Reynier, T. Petit, J-S. Frenel, E. Pons-Tostivint, C. Courtinard, M. Chaix, T. Bachelot
Journal: Annals of Oncology (2020)
Downregulation of IGF2 expression in third trimester placental tissues from Zika virus infected women in Brazil
Authors: Andréia A. Suzukawa, Camila Zanluca, Natasha A.N. Jorge, Lucia de Noronha, Andrea C. Koishi, Caroline B.V. de Paula, Patrícia Z. Rebutini, Seigo Nagashima, Aruana F.F. Hansel-Frose, Vinícius S.C. Parreira, Juliano Bordignon, Margaret R. MacDonald, Charles M. Rice, Fabio Passetti, Claudia Nunes Duarte dos Santos
Journal: Journal of Infection (2020)

Screening for genes differentially expressed in placental tissues, aiming to identify transcriptional signatures that may be involved in ZIKV congenital pathogenesis.Transcriptome data from placental tissues of pregnant women naturally infected with Zika virus during the third trimester were compared to those from women who tested negative for Zika infection. The findings were validated using both a cell culture model and an immunohistochemistry/morphological analysis of naturally infected placental tissues.Transcriptome analysis revealed that Zika virus infection induces downregulation of insulin-like growth factor II (IGF2) gene, an essential factor for fetal development. The Caco-2 cell culture model that constitutively expresses IGF2 was used for the transcriptome validation. Asiatic and African Zika virus strains infection caused downregulated IGF2 gene expression in Caco-2 cells, whereas other flaviviruses, such as dengue serotype 1, West Nile and wild-type yellow fever viruses, had no effect on this gene expression. Immunohistochemical assays on decidual tissues corroborated our transcriptome analysis, showing that IGF2 is reduced in the decidua of Zika virus-infected women.Our results draw attention to IGF2 modulation in uterine tissues, and this finding is expected to support future studies on strategies to ameliorate the harmful effects of Zika virus infection during pregnancy.
978TiP Durvalumab with cetuximab and radiotherapy for locally advanced squamous cell carcinoma of the head and neck: A phase I/II trial
Authors: P. Bonomo, I. Desideri, M. Mangoni, M. Loi, C. Saieva, L. Marrazzo, C. Talamonti, G. Salvatore, M. Sottili, M.A. Teriaca, G. Stocchi, C. Cerbai, V. Salvestrini, M. Ganovelli, D. Massi, O. Gallo, R. Santoro, G. Spinelli, S. Pallotta, L. Livi
Journal: Annals of Oncology (2020)
LBA50 ACTIVE: Apatinib plus gefitinib versus placebo plus gefitinib as first-line treatment for advanced epidermal growth factor receptor-mutant (EGFRm) non-small-cell lung cancer (NSCLC): A multicentered, randomized, double-blind, placebo-controlled phase III trial (CTONG1706)
Authors: L. Zhang, H. Zhao, Z. Zhang, W. Yao, X. Min, K. Gu, G. Yu, C. Cheng, J. Cui, L. Miao, X. Song, L. Zhang, X. Yuan, Y. Fang, X. Fu, C. Hu, X. Zhu, Y. Fan, Q. Yu
Journal: Annals of Oncology (2020)
1286P Activity of tepotinib in brain metastases (BM): Preclinical models and clinical data from patients (pts) with MET exon 14 (METex14) skipping NSCLC
Authors: S. Viteri, J. Mazieres, R. Veillon, E. Felip, X. Le, M.C. Garassino, T.S. Stanton, M. Morise, J-S. Lee, S. Matsumoto, F. De Marinis, T. Wehler, A. Clark, M. Friese-Hamim, C. Stroh, R. Bruns, G. Otto, P.K. Paik
Journal: Annals of Oncology (2020)
1572P Psychological impact of the COVID-19 pandemic on health care workers in oncology in Tunisia
Authors: A. Souilhi, A. Gabsi, F. Letaief-Ksontini, N. Chraiet, Y. Yahiaoui, F. Mghirbi, A. Mokrani, K. Meddeb, M. Ayadi, H. Rais, A. Mezlini
Journal: Annals of Oncology (2020)
1240P Prognostic impact of the CONtrolling NUTritional status (CONUT) score in patients with stage III non-small cell lung cancer (NSCLC)
Authors: V. Palomar Abril, T. Soria Comes, S. Tarazona Campos, M. Martin Ureste, M.E. Iriarte Moncho, V. Giner Bosch, I. Maestu Maiques
Journal: Annals of Oncology (2020)
111P Adenosine pathway and exhaustion markers in peripheral T-cell correlate with benefit from immunotherapy in advanced non-small cell lung cancer
Authors: L. Moliner, M.A. Galindo-Campos, M. Hardy-Werbin, R. Del Rey-Vergara, O. Arpí, X. Villanueva, S. Gonzalez, Á. Taus, P. Rocha, E. Arriola
Journal: Annals of Oncology (2020)
1420TiP A phase I/II trial of radium-223 (Ra-223) in combination with pembrolizumab in patients (pts) with stage IV non-small cell lung cancer (NSCLC)
Authors: M. Reck, K.F. Mileham, D.A. Clump, L. Decoster, A. Estival, E. Felip, P. Fried, L. Paz-Ares, M. Sebastian, N. Vinolas Segarra, V. Surmont, A. Wagner, S.M. Galdy, E.F. Smit
Journal: Annals of Oncology (2020)
328P Patient-reported outcomes of a switch to maintenance endocrine therapy following induction chemotherapy versus continuation of chemotherapy in ER-positive HER2-negative metastatic breast cancer: A randomized, open-label, phase II clinical trial
Authors: S. Saji, N. Taira, S. Morita, M. Kitada, T. Takano, M. Takada, T. Ohtake, T. Toyama, Y. Kikawa, Y. Hasegawa, T. Fujisawa, M. Kashiwaba, T. Ishida, R. Nakamura, Y. Yamamoto, U. Toh, H. Iwata, N. Masuda, S. Ohno, M. Toi
Journal: Annals of Oncology (2020)
Cardiac arrest in infant due to giant fetus-in-fetu
Authors: Yuhao Wu, Xin Jin, Chun Wu, Guanghui Wei
Journal: Thorax (2020)

A 7-month-old boy was referred to our institution following a cardiac arrest which was treated by timely cardiopulmonary resuscitation at another hospital. Previously, he had a progressive cough with a low-grade fever despite the use of antibiotics for 4 days. He was transferred to our institution for further investigation. He had no other associated diseases, nor use of medication. His mother did not report any abnormal findings from ultrasonography during prenatal examinations. Auscultation revealed shallow respiration with moist rales in the left lung. The echocardiogram revealed a 3.8 mm atrial septal defect with the heart shifted to the right. CT scan indicated a giant tumour in the posterior mediastinum (figure 1A, B). Serum alpha-fetoprotein (AFP) and β-chorionic gonadotropin (HCG) were negative. To exclude malignant conditions where chemotherapy would be warranted, a mini-thoracotomy for biopsy was performed. However, the biopsy indicated tissues of fibre, fat and …
1780TiP Ambulatory follow-up care and monitoring of cancer patients during SARS-CoV-2 pandemic by collecting blood samples at home and monitoring systemic therapy using a smartphone application (COREO-trial)
Authors: M. Peeters, C. Vulsteke, M. Rasschaert, J. Ravelingien, P. Van Vooren, G. Vanhoutte, L. De Backer, P.A. van Dam
Journal: Annals of Oncology (2020)
Angiotensin Receptor-Neprilysin Inhibitor Therapy for Heart Failure With Preserved Ejection Fraction Improves Renal Outcomes
Authors: Sheldon W. Tobe, Stephanie Poon
Journal: Circulation (2020)

eart failure with preserved ejection fraction (HFpEF) remains a clinical challenge for cardiologists, emergency room staff, and primary health care providers.Outcomes including readmissions and mortality are not good, 1 and treatment options have been limited.It is now postulated that our failure to identify any effective therapies may be related to the mechanistic heterogeneity behind the diverse pathophysiological phenotypes of HFpEF.The fundamental pathophysiological perturbation leading to HFpEF was traditionally attributed to hypertensive left ventricular remodeling. 2 However, our current understanding of HFpEF pathophysiology now incorporates systemic microvascular endothelial inflammation related to coexisting conditions as an additional mechanism. 2Excessive reactive oxygen species in the coronary endothelium lowers nitric oxide bioavailability, leading to reduced cyclic guanosine monophosphate in cardiomyocytes inducing their hypertrophy. 3Once hypertension and diabetes have caused cardiomyocytes to progress from left ventricular hypertrophy to diastolic dysfunction, episodes of heart failure from an overly stiff left ventricle leading to higher left atrial pressures, are likely triggered by dietary volume excess in the right circumstances.These include uncontrolled heart atrial fibrillation with tachycardia, shortening diastolic perfusion time of the myocardium, and episodes of hypoxemia with sleep apnoea exacerbated by sodium loading in the setting of chronic kidney disease.Following the successful admission for heart failure, patients feel well enough to fall into the same behavior patterns that ultimately lead to another admission with recurrent heart failure.Potential pathophysiologic mechanisms in HFpEF that are possible therapeutic targets include renal antinatriuresis and volume overload, inflammation from proinflammatory cytokines, poor skeletal muscle function, reduced peripheral oxygen delivery including vascular rarefaction, and chronotropic incompetence. 4esearch into how to improve outcomes in patients with HFpEF have until now been discouraging and it seemed that the underlying pathophysiology of the condition was not alterable.Cardiac rehabilitation improves quality of life and exercise capacity potentially by improving skeletal muscle quality and intrinsic oxygen utilization, as well as, the underlying comorbidities diabetes and hypertension.Among drug therapy, diuretics have had the best track record so far.In the CHAM-PION trial (CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients), hemodynamic-guided diuretic therapy reduced hospitalization for HF by 46% (95% CI, 0.38-0.70). 5Also, in the ALLHAT hypertension trial (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial), the diuretic chlorthalidone was superior to lisinopril in the subgroup of patients with HFpEF, with fewer new onset heart failure admissions. 6
77P Clinical characteristics and therapeutic implications of PALB2 variants in patients with advanced solid tumors
Authors: J.S. Gheeya, R. Goswamy, B. Garmezy, P.G. Pilie, W. Wang, S. Lee, M. Javle, J. Rodon, K.R. Mills Shaw, F. Meric-Bernstam, T.A. Yap
Journal: Annals of Oncology (2020)
795TiP Phase III study of the programmed cell death protein 1 inhibitor PF-06801591 plus bacillus Calmette-Guérin for non-muscle invasive bladder cancer
Authors: G.D. Steinberg, D. Saltstein, N. Shore, R. Cesari, J. Vermette, K. Pierce, J.A. Blake-Haskins, S. Hariharan, J. Bedke, T. Powles
Journal: Annals of Oncology (2020)
1055P Updated results of subcutaneous (SC) anti-programmed cell death 1 (PD-1) receptor antibody PF-06801591 for locally advanced or metastatic non-small cell lung cancer (NSCLC) or urothelial carcinoma (UC)
Authors: B.C. Chul Cho, K.D. Penkov, I. Bondarenko, A. Kurochkin, J. Pikiel, H.K. Ahn, R. Li, I.A. Jacobs, M. Bowers, M. Li, M. Johnson
Journal: Annals of Oncology (2020)
1108P Real world (RW) sequencing outcomes with immunotherapy and targeted therapy (TT) in BRAF+ metastatic melanoma (The NOBLE study series)
Authors: A. Betof Warner, A.A. Tarhini, M. Johnson, B. Kang, A. Nakasato, M. Vance, Y-L. Ling, J. Tang, J. Patel
Journal: Annals of Oncology (2020)
Roles of Regulatory RNAs in Nutritional Control
Authors: Elizabeth M. McNeill, Kendal D. Hirschi
Journal: Annual Review of Nutrition (2020)

Small RNAs (sRNAs), including microRNAs (miRNAs), are noncoding RNA (ncRNA) molecules involved in gene regulation. sRNAs play important roles in development; however, their significance in nutritional control and as metabolic modulators is still emerging. The mechanisms by which diet impacts metabolic genes through miRNAs remain an important area of inquiry. Recent work has established how miRNAs are transported in body fluids often within exosomes, which are small cell-derived vesicles that function in intercellular communication. The abundance of other recently identified ncRNAs and new insights regarding ncRNAs as dietary bioactive compounds could remodel our understanding about how foods impact gene expression. Although controversial, some groups have shown that dietary RNAs from plants and animals (i.e., milk) are functional in consumers. In the future, regulating sRNAs either directly through dietary delivery or indirectly by altered expression of endogenous sRNA may be part of nutritional interventions for regulating metabolism.
179P Prognostic impact of body composition (BC) changes during neoadjuvant chemotherapy (NACT) in breast cancer patients (pts)
Authors: L. Carbognin, I. Trestini, I. Sperduti, A. Caldart, M. Cintoni, A. Drudi, G. Aluffi, E. Fiorio, V. Parolin, D. Tregnago, A. Avancini, S. Pilotto, M. D'Onofrio, M.C. Mele, G. Scambia, G. Tortora, M. Milella, E. Bria
Journal: Annals of Oncology (2020)
487P Use of patient-derived tumour organoids to identify acquired treatment resistance and determine optimal post-progression combinations in metastatic colorectal cancer
Authors: G. Martini, I. Puig Borreil, L. Ramirez, I. Chicote, F.M. Mancuso, G. Caratu, X. Serres-Créixams, R. Fasani, J. Jimenez, F.J. Ros Montañá, I. Baraibar Argota, D. Ciardiello, N. Mulet Margalef, R. Dienstmann, A. Vivancos, E. Elez, H. Palmer, J. Tabernero, G. Argiles Martinez
Journal: Annals of Oncology (2020)
Assessment of Cardiac Function in Chemotherapy Naive Women With Breast Cancer Undergoing Contemporary Radiation Therapy
Authors: Alexandra C. Murphy, Terase F. Lancefield, Michael Chao, Farshad Foroudi, Anoop N. Koshy, Simon Undrill, Mark Horrigan, Belinda Yeo, Matias B. Yudi, Leighton Kearney, Omar Farouque
Journal: JACC CardioOncology (2020)

y -n c -n d / 4 .0 / ) .I S S N 2 6 6 6 -0 8 7 3 population had no prior exposure to cardiotoxic therapy such as anthracycline chemotherapy or trastuzumab, which have been independently associated with cardiac dysfunction (5).Additionally, the MHD in our study of 1.3 Gy was low compared with the majority of historical studies examining RIHD (1).Research using cardiac biomarkers in the detection of RIHD have largely examined cardiac troponins and natriuretic peptides.Although widely available and commonly used, we did not detect any significant changes with RT.The reason for this admittedly is unclear; these markers may be less relevant to RT cardiotoxicity, or it may also be that there is no detectable injury or stress with RT in the acute setting that can be quantified by these circulating markers.Demissei et al. (3) have studied alternative markers indicative of vascular dysfunction and inflammation with promising results.Given the difference in the magnitude of radiation exposure and chemotherapy use across different disease types and sites, isolating a chemotherapy-naive breast cancer population is a strength of this study.However, the interpretation of our results is limited by the small sample size, observational design, and intermediate duration of follow-up.In this single-center study, we found no evidence of subclinical myocardial dysfunction or injury during and up to 12 months post-RT.This suggests that RT delivered with contemporary techniques is not associated with early cardiac sequelae.
345P Optimal dose of eribulin as first line treatment in elderly patients ≥ 70 years with advanced breast cancer: A multicenter phase II trial [SAKK 25/14]
Authors: U. Hasler-Strub, A. Mueller, Q. Li, B.J.K. Thuerlimann, S. Gerber, R. von Moos, M. Fehr, C. Rochlitz, K. Zaman, S. Aebi, A.M. Hochstrasser, U. Gick, K. Ribi, D. Baertschi, S. Greuter, A. Schreiber, C.B. Caspar, A. Trojan, R. Condorelli, T. Ruhstaller
Journal: Annals of Oncology (2020)
700O Kidney ccRCC immune classification (KIC) enhances the predictive value of T effector (Teff) and angiogenesis (Angio) signatures in response to nivolumab (N)
Authors: M. Meylan, B. Beuselinck, C. Dalban, Y. Vano, N. Rioux Leclercq, C. Sautès-Fridman, E. Roussel, A. Verbiest, N. Chaput, S. Terry, C. Chevreau, M. Gross-Goupil, A. Fléchon, B. Laguerre, S. Chabaud, F. Tantot, D. Lambrechts, B. Escudier, W-H. Fridman, L. Albiges
Journal: Annals of Oncology (2020)
827P First real-life data on olaparib in 1st line (1stL) maintenance BRCA1/2 mutated epithelial ovarian cancer (EOC) in France: Descriptive analysis of 201 patients (pts) enrolled in the cohort temporary authorization for use (ATUc)
Authors: C. Bellier, L. Gladieff, F. Le Du, C. Garnier Tixidre, D. Berton-Rigaud, C. Bonnard, A. Lahrache, A. Debbache, A. Kacher-Damache, M. Delplanque, D. Suau, A-C. Richard, O. Brenner, A. Lahouegue, M. Urbieta, C. Gavoille, G. Freyer, A. Floquet, S. Frank, M. Kfoury
Journal: Annals of Oncology (2020)
A Truncated Singleton NLR Causes Hybrid Necrosis in<i>Arabidopsis thaliana</i>
Authors: Ana Cristina Barragan, Maximilian Collenberg, Jinge Wang, Rachelle R Q Lee, Wei Yuan Cher, Fernando A Rabanal, Haim Ashkenazy, Detlef Weigel, Eunyoung Chae
Journal: Molecular Biology and Evolution (2020)

Hybrid necrosis in plants arises from conflict between divergent alleles of immunity genes contributed by different parents, resulting in autoimmunity. We investigate a severe hybrid necrosis case in Arabidopsis thaliana, where the hybrid does not develop past the cotyledon stage and dies 3 weeks after sowing. Massive transcriptional changes take place in the hybrid, including the upregulation of most NLR (nucleotide-binding site leucine-rich repeat) disease-resistance genes. This is due to an incompatible interaction between the singleton TIR-NLR gene DANGEROUS MIX 10 (DM10), which was recently relocated from a larger NLR cluster, and an unlinked locus, DANGEROUS MIX 11 (DM11). There are multiple DM10 allelic variants in the global A. thaliana population, several of which have premature stop codons. One of these, which has a truncated LRR-PL (leucine-rich repeat [LRR]-post-LRR) region, corresponds to the DM10 risk allele. The DM10 locus and the adjacent genomic region in the risk allele carriers are highly differentiated from those in the nonrisk carriers in the global A. thaliana population, suggesting that this allele became geographically widespread only relatively recently. The DM11 risk allele is much rarer and found only in two accessions from southwestern Spain-a region from which the DM10 risk haplotype is absent-indicating that the ranges of DM10 and DM11 risk alleles may be nonoverlapping.
683P Correlation between castration resistant prostate cancer (CRPC) free survival (CRPC-FS) and metastasis free survival (MFS) in men initiating androgen deprivation therapy (ADT) for biochemical recurrence (BCR) after radical prostatectomy (RP): Results from the SEARCH database
Authors: S.J. Freedland, L. Howard, C.J.D. Wallis, A. De Hoedt, W.J. Aronson, T.J. Polascik, C.J. Amling, C.J. Kane, M.R. Cooperberg, M.K. Terris, Y. Wu, Z. Klaassen
Journal: Annals of Oncology (2020)
Effects of Time-Restricted Eating on Weight Loss and Other Metabolic Parameters in Women and Men With Overweight and Obesity
Authors: Dylan A. Lowe, Nancy Wu, Linnea Rohdin-Bibby, A. Holliston Moore, Nisa Kelly, Yong En Liu, Errol Philip, Eric Vittinghoff, Steven B. Heymsfield, Jeffrey E. Olgin, John A. Shepherd, Ethan J. Weiss
Journal: JAMA Internal Medicine (2020)

The efficacy and safety of time-restricted eating have not been explored in large randomized clinical trials.
WHO Digital Health Guidelines: a milestone for global health
Authors: Alain Labrique, Smisha Agarwal, Tigest Tamrat, Garrett Mehl
Journal: npj Digital Medicine (2020)

In 2019, the World Health Organization (WHO) released the first-ever evidence-based guidelines for digital health. The guideline provides nine recommendations on select digital health interventions that involve the use of a mobile phone or device. It also provides information on implementation considerations, quality and certainty of extant evidence, factors related to acceptability and feasibility of the intervention, and gaps in the evidence that can inform future research. Given the pivotal role digital health can play in supporting health systems, seen especially in light of the COVID-19 pandemic, these guidelines can help provide a roadmap for governments and policymakers in introducing and scaling up digital health interventions to support population health outcomes.
1594P Harmonising patient-access programmes
Authors: S. Barjesteh Van Waalwijk Van Doorn-Khosrovani, A. Pisters-van Roy, L. Timmers, L. van Saase, T.H.L. Tran, L.J. Zeverijn, P. Evers, H. Gelderblom, H.M.W. Verheul, E.F. Smit, N. Blijlevens, F.A. Eskens, H.J. Bloemendal, E.E. Voest
Journal: Annals of Oncology (2020)
Medical school places must be accompanied by more funding
Authors: Sarah G Michael, William Reynolds, Kirolos Michael
Journal: BMJ (2020)

Questions remain as to the practicality of lifting the cap on medical school places from the current 9500 in the UK.12 Even before covid-19, most medical schools required students to travel to distant district general hospitals and general practices to provide adequate learning opportunities to large cohorts.

The unfolding of the covid-19 pandemic has changed medical school beyond recognition, with …